reed autophagy is an evolutionarily conserved process for catabolizing damaged proteins and organelles in a lysosomedependent manner. dysregulation of autophagy may cause various diseases, such as cancer and neurodegeneration. however, the rel evance of autophagy to diseases remains controversial because of the limited availability of chemical modulators. herein, the authors developed a fluorescencebased assay for measuring activity of the autophagy protease, autophagin1(atg4B). the assay employs a novel reporter substrate of atg4B composed of a natural substrate (lc3B) fused to an assayable enzyme (pla 2 ) that becomes active upon cleavage by this cysteine protease. a highthroughput screening (hts) assay was validated with excellent Z′ factor (>0.7), remaining robust for more than 5 h and suitable for screening of large chemical libraries. the hts assay was validated by performing pilot screens with 2 small collections of compounds enriched in bioactive molecules (n = 1280 for lopac™ and 2000 for spectrum™ library), yielding confirmed hit rates of 0.23% and 0.70%, respectively. as counterscreens, pla 2 and caspase3 assays were employed to eliminate nonspecific inhibitors. in conclusion, the lc3B pla 2 reporter assay provides a platform for compound library screening for identification and characterization of atg4B specific inhibitors that may be useful as tools for interrogating the role of autophagy in disease models. (Journal of Biomolecular Screening 2011;16:174182) 
IntroductIon
A utophagy is an evolutionarily conserved process whereby cells catabolize damaged proteins and organe lles for purposes of generating substrates for sustaining adenos ine triphosphate (atp) production during times of nutrient deprivation. 1,2 three types of autophagy have been described based primarily on cellular morphology considerations, includ ing macroautophagy, microautophagy, and chaperonemediated autophagy. 3 For the most part, autophagyrelated genes (atg) are required for these 3 forms of autophagy, with some minor differ ence. 4, 5 the genes responsible for autophagy have been identi fied, largely through genetic analysis of yeast, Saccharomyces cerevisiae, and are conserved in mammals, plants, and essen tially all eukaryotes. 6 roles for autophagy have been suggested in either causation or prevention of disease. For example, autophagy has been implicated in eliminating senescent and insoluble proteins that are not degraded via proteasomebased mechanisms, represent ing an important "housekeeping" function for some types of cells, such as neurons, where it may be helpful for preventing protein inclusion body diseases associated with neurodegenera tion. 7, 8 autophagy also plays helpful roles in the context of hostpathogen interactions, where autophagic vesicles help to surround intracellular virus particles and bacteria, targeting them for lysosomal destruction. 9, 10 in contrast, autophagy may promote the pathogenesis and progression of tumors, allowing cancer cells to survive nutrientpoor and hypoxic environmentssuch as those found in the centers of rapidly growing malignant lesions that have outstripped their vascular supply. 11 conversely, some components of the autophagy machinery have also been reported to be required for nonapoptotic cell death, suggesting the concept of autophagic cell death. 12 altogether, the role of autophagy in disease remains largely controversial.
chemical inhibitors of autophagy are essentially nonexist ent, with the few agents available for aiding research. the compound 3methyladenine (3Ma) has been touted as an autophagy inhibitor but requires millimolar concentrations to inhibit class iii phosphatidyl inositol kinases (pi3Ks) involved in autophagy. 13 Bafilomycin a1 is also commonly employed for suppressing autophagic flux due to its inhibition of the vacuolar type h + atpase (vatpase), blocking acidification of lyso somes and endosomes. however, longterm treatment (>4 h) of cells with bafilomycin a1 also interferes the trafficking of proteosomes, endosomes, and other cellular processes. 14, 15 a need therefore exists for chemicals that target specific compo nents of the autophagy machinery for use as research tools for addressing questions about autophagy mechanisms and investi gating the role of autophagy in diseases.
autophagins are a class of cytosolic cysteine proteases required for autophagy. 16 autophagins cleave atg8 to promote its conjugation with phosphatidylethanolamine (pe) in the mem branes of autophagic vesicles by a ubiquitinlike system, which is required for autophagosome formation and participates in tar geting these vesicles to lysosomes for fusion and degradation of their contents. 17 autophagins also promote deconjugation of atg8pe to liberate atg8 from membrane at or before the final stage of fusion between autophagosome and lysosomes, suggest ing that deconjugation of atg8pe is required for the fusion. 18 the human genome contains 4 independent genes encoding the atg4 orthologs (termed autophagins), including atg4a/ autophagin2, atg4B/autophagin1, 4c/autophagin3, and 4d/ autophagin4. 16 atg4B cleaves most of human atg8 homologs in vitro, including (1) microtubuleassociated light chain 3 (lc3; which has a, B, and c isoforms), (2) gaBa(a) receptorassociated proteinlike 1 (gaBarapl1), (3) gaBa(a) recep tor-associated protein (gaBarap), and (4) golgiassociated atpase enhancer of 16 kda (gate16, also known as gaBa(a) receptor-associated proteinlike 2). 1921 in contrast, atg4a has activity mainly for gate16 in vitro. 22 atg4B knockout mice show reduction of proteolysis of all atg8 homologs except gate16, suggesting that atg4a compensates for cleavage of gate16 in atg4B knockout mice. 21 By comparison, atg4c and atg4d show minor protease activity or require posttranslational modification (caspase3 cleavage) for activation, 20, 23 indicating atg4B is functionally dominant in the regulation of autophagy.
in this study, we have selected autophagin1/atg4B as a target for developing novel inhibitors of autophagy. We devised a atg4B highthroughput screening (hts) assay using a lc3B pla 2 reporter substrate (shu, 2010 #16880) in 384well format that has excellent performance characteristics (Z′ factor >0.7) and verified by pilot library screening and counterscreens that the assay is suitable for hts of chemical libraries.
exPerIMentAL ProcedureS

Plasmid constructions
plasmids for bacterial expression of autophagin1 (atg4B) and substrate protein lc3B were constructed as previously described. 19 Briefly, pcr products were cloned into bacterial expression vector petduet1 (novagen, san diego, ca) in frame with an nterminal his tag. the mature human phospholi pase a 2 (pla 2 ) group X g10 (amino acids 43165) was amplified from a human fetal brain cdna library (open Biosystems, san diego, ca) and fused with lc3B in petduet1. sitedirected mutagenesis of atg4B c74a or lc3B g120a was carried out by the Quickchange kit according to the manufacturer's instructions (stratagene, la Jolla, ca).
Protein expression and purification in Escherichia coli
atg4B or catalytic mutant atg4B c74a expression plasmid was transformed into Escherichia coli Bl21 (de3; invitrogen, san diego, ca). protein expression was induced by 0.1 mM isopropyl βd1thiogalactopyranoside (iptg; invitrogen) at 15°c for 6 h. his 6 tagged proteins were purified using ninta agarose (Qiagen, valencia, ca) and eluted with a 20 to 250 mM imidazole gradient in 20 mM tris (ph 8.0), 150 mM nacl, and 10 mM βmercaptoethanol. his 6 tagged lc3Bpla 2 protein was induced by 1 mM iptg at 37°c for 4 h to obtain inclusion bodies. the inclusion bodies were solubilized with 20 mM tris buffer (ph 8.0) con taining 0.5 M nacl, 5 mM imidazole, 6 M guanidine hydro chloride, and 1 mM βmercaptoethanol and loaded into the ninta column. the denatured proteins were refolded with refolding buffer (20 mM tris [ph 8.0], 0.5 M nacl, 20 mM imidazole, 1 mM βmercaptoethanol) in the presence of linear 60 M gradient urea. the refolded proteins were eluted with a 20 to 500mM gradient imidazole in 20 mM tris (ph 8.0), 150 mM nacl, and 10 mM βmercaptoethanol.
For production of active pla 2 protein, lc3Bpla 2 fusion protein (2.5 µM) was incubated with atg4B (100 nM) in pla 2 reaction buffer (20 mM trishcl [ph 8.0], 2 mM cacl 2 , and 1 mM dithiothreitol [dtt]) at room temperate for 16 h. the cleaved pla 2 protein was purified with ninta column (Qiagen) to remove his 6 tagged lc3B and atg4B. caspase3 protein was purified as described previously. 24, 25 Atg4B cleavage of synthetic protein substrates atg4B (wildtype [Wt]) or catalytic mutant atg4B c74a was incubated with 400 nM protein substrates in a 50µl reaction buffer containing 50 mM tris (ph 8.0), 150 mM nacl, and 1 mM dtt at 37°c for 1 h. reactions were stopped by addition of 50 µl of 2× laemmli sodium dodecyl sulfate (sds) sample and subjected to 13% sds-polyacrylamide gel electrophoresis (page) followed by gelcode Blue staining (thermo Fisher scientific, asheville, nc) or transfer to nitrocellulose mem branes (sigmaaldrich, st. louis, Mo) for immunoblotting analysis using antimyc antibody (roche, indianapolis, in). proteins were detected using peroxidaseconjugated antimouse igg secondary antibody by super signal and chemiluminescence substrate (pierce, rockford, il) with exposure to Xray film.
Atg4B activity measured using LC3B-PLA 2 substrate
the assay was modified from a previous report. 26 Briefly, recombinant atg4B was mixed with lc3Bpla 2 fusion protein to a final volume of 20 µl pla 2 reaction buffer (20 mM trishcl [ph 8.0], 2 mM cacl 2 , and 1 mM dtt) containing 20 µM 2(6(7nitrobenz2oxa1,3diazol4yl)amino) hexanoyl 1hexadecanoylsnglycero3phosphocholine (nBdc 6 hpc) (invitrogen) in wells of blackwalled 384well plates (greiner Bioone, Frickenhausen, germany). Fluorescence intensity was measured for various times using an analyst™ ht (Molecular devices, sunnyvale, ca) at room temperature with excitation and emission wavelengths of 485 and 530, respec tively. data were analyzed by graphpad prism software (graphpad software, san diego, ca). to determine robustness of the assay, Z′ factor was calculated as a defined equation: 1 -3(sd +atg4B + sd −atg4B )/mean +atg4B -mean −atg4B , where sd is the standard derivation of signal for both positive ( +atg4B ) and negative ( −atg4B ) controls. 27
High-throughput screening
For hts, 20 nl of each compound (10 mM in dMso) of 1280 compounds from the lopac™ library (sigmaaldrich) or 2000 compounds from the spectrum™ library (spectrum chemicals & laboratory products, gardena, ca) were plated into black 384well, roundwell plates using a labcyte echo 550 acoustic pipetter (agilent technologies, Wilmington, de). recombinant atg4B (0.2 nM, 10 µl) was dispensed to each well using thermoscientific Matrix WellMate bulk dispenser (thermo Fisher scientific). lc3Bpla 2 fusion protein (50 nM, 10 µl) diluted in 2× pla 2 reaction buffer (40 mM trishcl [ph 8.0], 4 mM cacl 2 , and 2 mM dtt) containing 40 µM nBdc 6 hpc (invitrogen) was then added to each well. Fluorescence intensity was measured within 30 to 60 min using an analyst™ ht (Molecular devices) at room temperature with excitation and emission wavelengths of 485 and 530, respectively. the inhibition of compounds was recorded as percentage compared to dMso control. twofold serial dilu tions (maximal final concentration 100 µM) of compounds were used for determination of doseresponsive curves. ic 50 values were calculated by nonlinear regression analysis employing graphpad prism software (graphpad software).
Counterscreens for PLA 2 and caspase-3 assay
For the pla 2 assay, 20 nl of each hit (10 mM in dMso) from lopac™ or spectrum™ libraries was plated into black 384well, roundwell plates using a labcyte echo 550 acoustic pipetter (agilent technologies). active pla 2 (500 nM, 10 µl) was dis pensed to each well, then mixed with nBdc 6 hpc (invitrogen; 20 µM, 10 µl) in pla 2 reaction buffer at room temperature for 2 h. Fluorescence intensity was measured with excitation and emis sion wavelengths of 485 and 530, respectively. caspase3 assay was determined using methods modified from a previous report. 25 Briefly, his 6 [chaps], 100 mM nacl, and 1 mM dtt) in wells of white 384 well plates containing 20 nl hit compound (10 mM in dMso). Fluorogenic aFc product was measured at 37°c for 1 h with excitation and emission wavelengths of 405 and 510, respectively.
reSuLtS
Development of Atg4B assay based on LC3B-PLA 2 fusion protein substrate
to develop a primary hts assay for autophagins, we generated an expression plasmid for production of lc3Bpla 2 fusion pro tein (substrate) in bacteria. the enzyme phospholipase a 2 (pla 2 ) is inactive when expressed as a fusion protein with polypeptide appendages added to its nterminus ( Fig. 1A) . 28 lc3B is among the endogenous substrates of autophagin1/atg4B. thus, we gen erated a novel substrate for autophagin screening by producing a recombinant lc3Bpla 2 fusion protein, such that atg4mediated cleavage of lc3B liberates active pla 2 (shu, 2010 #16880). using bacterially expressed, purified his 6 atg4B (protease), we determined that cleavage of lc3Bpla 2 by atg4B is done in a concentrationdependent manner, as shown by monitoring cleavage products by sdspage with protein stains or immuno blotting ( Fig. 1B) . Moreover, cleavage of the lc3Bpla 2 sub strate was not observed with an atg4B catalytic mutant (cys/ala). importantly, nBd fluorescence release from the pla 2 substrate nBdc 6 hpc also increased in a concentrationdependent man ner, as measured in a plate reader assay ( Fig. 1c) .
We also explored the reactivity of atg4B on a mutant of lc3Bpla 2 in which the glycine residues at which lc3B cleavage normally occurs was converted to alanine. atg4B only slightly cleaved the lc3Bpla 2 (gly/ala) mutant as measured by generation of pla 2 activity ( Fig. 1B) . We pre sume that the pla 2 activity generated from exposure of the mutant substrate to atg4B may be due to cleavage at a glycine residue provided by pla 2 because glycine is the first reside in pla 2 where fusion to lc3B occurred (the wildtype junction sequence is etFggile, where bold indicates the site of cleav age, and the mutant sequence is etFAgile).
to determine the optimal concentration of atg4B and lc3B pla 2 for the assay, the concentration of atg4B was titrated by 2fold serial dilution from 1250 to 0 pM ( Fig. 2A) . atg4B mediated increase of fluorescence in lc3Bpla 2 containing reactions was observed in a time and concentrationdependent manner. similar to prior reports using ubiquitinpla 2 for assays 26 of deubiquiteness, a kinetic lag effect was observed at low con centrations of atg4B (<160 pM), which has been attributed to pla 2 substrate nBdc 6 hpcforming micelles. next, lc3B pla 2 was 2fold serial diluted from 200 to 0 nM for assessing optimal substrate concentration ( Fig. 2B) , showing the apparent K m is approximately 25 nM.
HTS implementation of the LC3B-PLA 2 reporter assay for Atg4B
to study assay performance for the hts environment, the atg4B assay was tested in 384well plates using 96 wells each of (a) the negative control (without atg4B); (b) the positive control (atg4B without inhibitors); (c) a control for protease inhibition (atg4B with general cysteine protease inhibitor nethylmaleimide (10 mM), which covalently modifies the active site cysteine of proteases; and (d) egta (5 mM), a che lator of calcium, which is essential for pla 2 activity (Fig. 3) . For this experiment, lc3Bpla 2 was employed at 25 nM and protein at 0.1 nM, based on the results from the doseresponse analysis. Fluorescent intensity was measured for up to 5 h (Fig. 3B) . the Z′ statistic was calculated from the data and determined to be >0.7 when measured from 0.5 to 5 h. thus, the assay exhibits performance characteristics sufficient for use in hts with robust performance for at least 5 h after pre paring reactions in microwells.
Screening and characterization of hits from the LOPAC™ and Spectrum™ libraries
next, we undertook a pilot screen of a chemical library (lopac™) enriched in bioactive molecules to test the per formance of the hts assay (Fig. 4A) . the compound library was screened at an average compound concentration of approximately 10 µM at room temperature for 1 h, which is within the linear range of the hts assay. the assays contained 0.1% dMso final volume. From this screen of 1280 chemical compounds, we obtained 4 hits (cutoff of 50% inhibition). the hits were cherry picked and retested at the screening concentra tion. of these, 3 hits were confirmed, constituting a hit rate of 0.23% (see Supplemental Figure S1A ). one of the hit com pounds (a1895) has been found previously by us to inhibit gapdh and uBc13 (data not shown), which are both enzymes that contain cysteine in their active sites, suggesting that this compound is nonselective. the remaining 2 hits from hts were first filtered with a pla 2 counterscreen assay to eliminate compounds directly inhibiting pla 2 or interfering with fluores cence (see Supplemental Figure S1B ). neither of the hits directly inhibited pla 2 . next, hits were also evaluated using a counterscreen assay for caspase3, another class of cysteine protease, to eliminate redoxactive compounds that attack cysteine within the catalytic centers of enzymes (see Supplemental Figure S1c ). Both of the remaining com pounds inhibited caspase3, indicating that they are nonselec tive. although no promising hits were obtained from the lopac™ library, the conditions used for library screening provided a reasonable hit rate.
We therefore also screened the spectrum™ library, which consists of 2000 bioactive compounds. again, the hts assay was performed at room temperature for 1 h. after screening and confirmation, 14 of initial 25 hits were confirmed, thus representing a confirmed hit rate of 0.7% (Fig. 4B,c) . the hits were evaluated with 2 counterscreens: pla 2 and caspase3. inhibitor controls for the counterscreen assays included egta (5 mM, pla 2 assay) and zvadfmk (10 µM, caspase3 assay) ( Fig. 4d,e) . the Z′ factors were 0.78 and 0.60 for the pla 2 and caspase3 assay, respectively. only 1 of the 14 confirmed hits showed inhibitory activity in the pla 2 counterscreen assay, indicating that it was a false positive ( Fig. 4d) . none of the hits inhibited caspase3 activity (Fig. 4e) .
We also tested the hits with lcBpla 2 reporter assay in kinetic mode using covalent inhibitor iodoacetamide (iaa) as a positive control, which attacks the active site cysteine of atg4B (see Supplemental Figure S2 ). each of the hits reduced the slope of the enzyme progress curves, showing slower but linear rates of substrate hydrolysis. Finally, the hits were tested using our autophagin1 hts assay with or without dtt to identify redoxactive compounds that generate superoxide and thus oxi dize cysteines in target proteins. 29, 30 two of the compounds (1504078 and 1504080) showed additive inhibition in the pres ence of dtt and thus are likely to inhibit in vitro through a redoxbased mechanism (see Supplemental Figure S3 ).
the hits were then cherry picked for doseresponse testing (table 1) . of the 13 remaining hits, 4 inhibited atg4B with ic 50 <10 µM, showing concentrationdependent inhibition with wellfitted curves using the hill equation (0.5 ≤ h ≤ 1.5, 6 hpc on ice, and then 20µl aliquots were dispensed into wells of a 384well plate containing compounds (10 µM average approximate concentration) of the lopac™ collection for 1 h. pla 2 activity was measured as a percent age relative to control wells that received dMso only. Z′ factor was calculated by including a row of wells without atg4B as a negative control (assay minimum) and a row of wells with atg4B without compounds (dMso only) as positive control (assay maximum). the 50% inhibition cutoff used for hit calling is indicated. (B) assays were performed as in A using the spectrum™ library. (c) lc3Bpla 2 (25 nM) and atg4B (0.1 nM) were mixed with hits from hts using the spectrum™ library in pla 2 reaction buffer (20 mM trishcl [ph 8.0], 2 mM cacl 2 , and 1 mM dithiothreitol) containing 20 µM nBdc 6 hpc for 1 h. the pla 2 activity was measured as percentage compared to positive control (atg4B alone). (d) the confirmed hits were mixed with active pla 2 (250 nM) assay in the reaction buffer containing 20 µM nBdc 6 hpc at room temperature for 2 h to eliminate the compound directly inhibiting pla 2 or interfering with fluorescence. the pla 2 activity was measured as a percentage compared to the positive control (pla 2 alone). egta (5 mM) was used as control for inhibiting pla 2 activity. (e) the confirmed hits were mixed with caspase3 (0.5 nM) in assay buffer containing acdevdaFc (100 µM) at 37°c for 1 h. the activity of caspase3 was measured by aFc fluorescence with excitation and emission filters of 400 nm and 505 nm, respectively, reporting results as a percentage com pared to positive control (+, caspase3 alone). zvadfmk (10 µM) was used for inhibiting caspase3 activity. r 2 > 0.9; Fig. 5 ). the ic 50 of compounds 201508, 1502245, 1504078, and 1504080 was estimated at 2.3, 5.5, 1.7, and 1.1 µM (mean ± seM), respectively. taken together, our hts assay provides the first platform for screening chemical librar ies for autophagin inhibitors.
dIScuSSIon autophagins play a crucial role in conjugation and deconju gation of atg8 paralogs to autophagic vesicles and are indis pensable for the process of autophagy. 31 chemical inhibitors of autophagy are largely lacking, thus representing a void in the armamentarium of experimental approaches available to study this process. in this study, we have devised an hts fluorogenic assay for measuring activity of autophagin1 (atg4B). the assay performs robustly in the 384well environment with Z′ factors consistently >0.7. the signaltonoise ratio and repro ducibility of the assay are sustained for at least 5 h, which is appropriate for hts applications. Moreover, acceptable hit rates were obtained in pilot screens of 3280 bioactive com pounds at ~10 µM, with confirmed hit rates of 0.23% to 0.70%. Finally, the expression plasmids and methods for bacterial expression that we have described for recombinant atg4B (protease) and lc3Bpla 2 (substrate) proteins provide excellent yields (~6 mg/l culture), thus making largescale chemical library screening entirely feasible. pla 2 has been used previously in other protease applications because of the inhibitory effect that nterminal appendages have on this enzyme. 26 When expressed as a fusion protein with a cleavable nterminus, pla 2 serves as a convenient reporter for monitoring protease activity. For example, ubiquitinpla 2 fusion protein is cleaved by deubiquitin enzymes (duBs) and efficiently produces active pla 2 . the lc3Bpla 2 fusion protein substrate that we have recently described and characterized represents the first application of the pla 2 fusion protein approach to autophagy proteases. 19 compared to aFc (7amino4trifluoromethyl coumarin)-conjugated tetrapeptide substrates that we investi gated in a previous study, 19 the catalytic efficiency of the lc3B pla 2 substrate is 5.7 × 10 5 higher (k cat /K m 5.26 × 10 5 M −1 /s −1 ). in this regard, the crystal structure of the lc3/atg4B complex has shown that fulllength lc3B induces conformational changes in atg4B that promote formation of the active catalytic site, 32 thus presumably explaining why our lc3Bpla 2 protein substrate is far superior to peptide substrates. thus, the lc3Bpla 2 substrate is not only more physiological but is also much more efficient from the perspective of enzyme kinetics.
We have also begun to create additional pla 2 fusion pro teins with other autophagin substrates appended, including gate16 and gaBarapl1, which can serve as alternatives to lc3Bpla 2 for some autophagins or as secondary assay reagents for independent confirmation of hits. in this regard, atg4 members have differential substrate specificities. For example, atg4a mainly cleaves gate16, whereas atg4d cleaves both gate16 and gaBarapl1. 20, 22 thus, gate 16pla 2 fusion protein may provide a suitable substrate for atg4a and atg4d assay development. indeed, we have gener ated and successfully tested a gate16pla 2 fusion protein for measuring activity of recombinant atg4a, 19 using essen tially the same assay conditions reported here (data not shown).
after counterscreening and elimination of false positives using a pla 2 counterscreen, 4 compounds were identified from among 3280 bioactive molecules, showing concentration dependent inhibitory activity (ic 50 <10 µM) against atg4B but not an alternative class of cysteine protease, caspase3. Further testing using our autophagin1 hts assay in the presence or absence of dtt eliminated 2 compounds (1504078 and 1504080) that showed additive inhibition in the presence of dtt, indicating that hydrogen superoxide generation in vitro may be partially involved in inhibition of atg4B. 29, 30 three of the compounds (1502245, 1504078, and 1504080) are also reported hits in other hts assays reported in the pubchem database, whereas another compound (201508) inhibits shp2 tyrosine phosphatase, 33 showing promiscuous activity. in addi tion, these compounds have structures that are not promising for lead optimization, with 2 compounds representing polyphe nols containing carboxylates (with or without internal cycliza tion to form lactone rings; 201508, 1502245) and 2 compounds representing stereoisomers of a natural product senoside glyco sylated with pyranose sugars (1504078 and 1504080). although none of these compounds is an attractive candidate for under taking structureactivity relation (sar) studies toward potent and selective autophagin inhibitors, these pilot screening results nevertheless provide proofofconcept evidence that the hts assay described here is capable of identifying compounds with the potential for selectivity against autophagins relative to other classes of cysteine proteases. autophagy plays cytoprotective roles in some cancerrele vant contexts. 29, 30, 32 in this regard, inhibition of autophagy has been reported to sensitize some tumor cells to chemotherapy, suggesting that chemical inhibitors of autophagins may provide novel candidates for cancer drug discovery. silencing atg5 or atg7 enhances apoptosis in chronic myeloid leukemia (cMl) cells treated with imatinib mesylate (iM). 34 autophagy inhibi tor, 3Ma, or sirna against atg7 also augments 5fluorouracil (5Fu)-induced apoptosis in colon cancer cells in vitro and in vivo. 35 inhibiting autophagy with the nonselective pi3K inhibi tor wortmannin (which crossreacts on the class iii pi3K of autophagy, vps34), as well as sirnas targeting vps34, Beclin1, or atg5, appears to be synergistic with gossypol, a natural prod uct that inhibits Bcl2 family proteins, in human breast cancer cell McF7. 36 in these cancer cell culture models, inhibition of autophagy synergizes with cytotoxic anticancer drugs, and thus it has been suggested that autophagy allows cancer cells to survive the stress of chemotherapy. thus, we anticipate that atg4Bspecific inhibitors may have tumor growth inhibitory activity, as well as an ability to improve cytotoxic responses to chemotherapy. it is hoped that applications of the hts assay reported here for screening large compound libraries will pro vide attractive chemical scaffolds for the pursuit of a novel class of anticancer agents based on inhibition of autophagy.
